Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogode OCV Booster-dose Study
PACTR202102660004195Phase 2Completed
- Sponsor
- MASS
- Start
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial in cholera (2 arms), sponsored by MASS. Primary endpoint: Early vibriocidal response. Started Feb 2021; status: completed.
02
Conditions
cholera
Beyond the preview
Go deeper on PACTR202102660004195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102660004195.